Silence Therapeutics plc (SLN) Tops Q3 EPS

Silence Therapeutics plc (NASDAQ: SLN) reported Q3 EPS of (£0.07), £0.10 better than the analyst estimate of (£0.17). Revenue for the quarter came in at £2.8 million versus the consensus estimate of £2.94 million.

For earnings history and earnings-related data on Silence Therapeutics plc (SLN) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Darling Ingredients (DAR) PT Raised to $88 at UBS